Public Employees Retirement System of Ohio Has $30,000 Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Public Employees Retirement System of Ohio lowered its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMOFree Report) by 86.2% during the third quarter, Holdings Channel reports. The institutional investor owned 50,200 shares of the biopharmaceutical company’s stock after selling 314,669 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Sangamo Therapeutics were worth $30,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Advisor Group Holdings Inc. boosted its stake in shares of Sangamo Therapeutics by 12.7% in the 1st quarter. Advisor Group Holdings Inc. now owns 23,897 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 2,684 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Sangamo Therapeutics by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 443,190 shares of the biopharmaceutical company’s stock valued at $2,576,000 after purchasing an additional 4,035 shares in the last quarter. AlphaCrest Capital Management LLC boosted its stake in shares of Sangamo Therapeutics by 25.4% in the 1st quarter. AlphaCrest Capital Management LLC now owns 14,419 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 2,919 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Sangamo Therapeutics by 33.9% in the 1st quarter. MetLife Investment Management LLC now owns 59,668 shares of the biopharmaceutical company’s stock valued at $347,000 after purchasing an additional 15,097 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Sangamo Therapeutics by 27.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,840,893 shares of the biopharmaceutical company’s stock valued at $16,506,000 after purchasing an additional 614,426 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on SGMO. StockNews.com began coverage on shares of Sangamo Therapeutics in a research report on Tuesday, February 13th. They set a “sell” rating on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price target (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of “Hold” and an average price target of $4.93.

Read Our Latest Report on Sangamo Therapeutics

Sangamo Therapeutics Trading Up 7.3 %

Shares of NASDAQ:SGMO opened at $0.67 on Friday. The stock has a market capitalization of $119.91 million, a P/E ratio of -0.46 and a beta of 1.44. Sangamo Therapeutics, Inc. has a 1-year low of $0.29 and a 1-year high of $1.82. The business has a 50-day moving average price of $0.80 and a two-hundred day moving average price of $0.61.

Sangamo Therapeutics Profile

(Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Featured Articles

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMOFree Report).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.